EMMA:OTC-Emmaus Life Sciences Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.091

Change

0.00 (0.00)%

Market Cap

USD 4.93M

Volume

N/A

Analyst Target

USD 24.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-14 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NONOF Novo Nordisk A/S

N/A

USD 649.39B
CMXHF CSL Limited

N/A

USD 94.38B
CSLLY CSL Ltd

N/A

USD 92.66B
UCBJY UCB SA ADR

N/A

USD 27.94B
UCBJF UCB SA

N/A

USD 26.91B
ARGNF argenx SE

N/A

USD 23.04B
GNMSF Genmab A/S

N/A

USD 17.89B
SBMFF Sino Biopharmaceutical Limited

N/A

USD 6.87B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

USD 6.83B
REGMF RemeGen Co. Ltd

N/A

USD 6.81B

ETFs Containing EMMA

SXLF:LSE SPDR S&P U.S. Financials .. 6.45 % 0.00 %

+0.06 (+0.00%)

USD 0.37B
IYJ 6.29 % 0.42 %

N/A

N/A
IVFGC 5.90 % 0.00 %

N/A

N/A
ZFIN:CA 5.14 % 0.00 %

N/A

N/A
BFIN-U:CA 5.12 % 0.00 %

N/A

N/A
LONG:CA CI Global Longevity Econo.. 5.06 % 0.00 %

N/A

CAD 3.80M
ZINN:CA 5.05 % 0.00 %

N/A

N/A
VSLU ETF Opportunities Trust -.. 4.87 % 0.00 %

N/A

USD 0.16B
FINZ 4.83 % 0.95 %

N/A

N/A
TPAY 4.68 % 0.00 %

N/A

N/A
SPHQ Invesco S&P 500® Quality.. 4.55 % 0.19 %

N/A

USD 9.91B
ZINT:CA 4.39 % 0.00 %

N/A

N/A
JOYY 4.26 % 0.00 %

N/A

N/A
HAU:CA 4.23 % 0.79 %

N/A

N/A
SXQG 6 Meridian Quality Growth.. 4.12 % 0.00 %

N/A

USD 0.04B
LINK:CA 4.02 % 0.00 %

N/A

N/A
UYG ProShares Ultra Financial.. 3.98 % 0.95 %

N/A

USD 0.65B
HFT:CA 3.89 % 0.00 %

N/A

N/A
QUAL 3.88 % 0.15 %

N/A

N/A
XDWF:LSE db x-trackers MSCI World .. 3.75 % 0.00 %

+0.06 (+0.00%)

USD 0.62B
WFIN:LSE SPDR® MSCI World Financi.. 3.74 % 0.00 %

+0.11 (+0.00%)

USD 0.33B
STNC Stance Equity ESG Large C.. 3.68 % 0.00 %

N/A

USD 0.11B
QMJ 3.66 % 0.00 %

N/A

N/A
DUAL 3.48 % 0.00 %

N/A

N/A
PQVM:LSE Invesco S&P 500 QVM UCITS.. 3.23 % 0.00 %

+0.25 (+0.00%)

USD 0.03B
VEGN 3.08 % 0.00 %

N/A

N/A
HAU-U:CA 3.00 % 0.00 %

N/A

N/A
JHMF 2.96 % 0.47 %

N/A

N/A
OPPX 2.37 % 0.00 %

N/A

N/A
IWQU:LSE iShares MSCI World Qualit.. 2.27 % 0.00 %

+0.11 (+0.00%)

USD 3.79B
VIG Vanguard Dividend Appreci.. 2.24 % 0.06 %

N/A

USD 78.38B
XDEQ:LSE Xtrackers MSCI World Qual.. 2.10 % 0.00 %

-3.00 (0.00%)

USD 1.70B
CAPS:CA 1.85 % 0.96 %

N/A

N/A
IGSG:LSE iShares Dow Jones Global .. 1.83 % 0.00 %

-6.00 (0.00%)

USD 1.30B
IGSU:LSE iShares Dow Jones Global .. 1.83 % 0.00 %

+0.06 (+0.00%)

USD 1.30B
RUE-U:CA 1.82 % 0.00 %

N/A

N/A
FLGE 1.79 % 0.00 %

N/A

N/A
XULR:CA 1.72 % 0.00 %

N/A

N/A
SUSL iShares ESG MSCI USA Lead.. 1.49 % 0.00 %

N/A

USD 1.01B
QRFT QRAFT AI-Enhanced U.S. La.. 1.46 % 0.00 %

N/A

USD 9.95M
FUSA:LSE Fidelity US Quality Incom.. 1.40 % 0.00 %

-0.01 (0.00%)

USD 0.35B
FUSI:LSE Fidelity US Quality Incom.. 1.40 % 0.00 %

+0.75 (+0.00%)

USD 1.10B
FUQA:LSE Fidelity US Quality Incom.. 1.40 % 0.00 %

+1.38 (+0.00%)

USD 0.35B
FUSD:LSE Fidelity UCITS SICAV - Fi.. 1.40 % 0.00 %

+0.05 (+0.00%)

USD 1.10B
FUSP:LSE Fidelity US Quality Incom.. 1.40 % 0.00 %

+0.04 (+0.00%)

USD 6.14M
XESW:LSE Xtrackers (IE) Plc - Xtra.. 1.25 % 0.00 %

+0.06 (+0.00%)

USD 6.61B
RWCD 1.15 % 0.00 %

N/A

N/A
UIQM:XETRA 0.87 % 0.00 %

N/A

N/A
TDV 0.00 % 0.00 %

N/A

N/A
ENOA:F BNP Paribas Easy - MSCI N.. 0.00 % 0.00 %

+0.21 (+0.00%)

USD 0.17B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -9.00% 52% F 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.00% 52% F 38% F
Trailing 12 Months  
Capital Gain -66.30% 29% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -66.30% 30% F 15% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -37.92% 12% F 4% F
Dividend Return -37.92% 12% F 4% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 40.79% 72% C 58% F
Risk Adjusted Return -92.96% 15% F 6% D-
Market Capitalization 4.93M 44% F 32% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.